Study S003331

A Phase II Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection and GZR33-70 Injection in Type 2 Diabetes Inadequately Controlled on Basal Insulin or Premixed Insulin Once Daily at Least With or Without Pre-dinner Meal-time Insulin

ClinicalTrials.gov record

Registration

Registration: NCT06558708
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: UNKNOWN
Enrollment: 60
Start: 2024-06-28
Primary completion: 2024-12
Lead sponsor: Gan and Lee Pharmaceuticals, USA
Conditions: Type 2 Diabetes
Interventions: DRUG:GZR101 Injection; DRUG:GZR33 Injection; DRUG:Insulin aspart
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change in HbA1c [Week 0, week 16]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.